The response of an acquired Factor V inhibitor to activated Factor IX concentrate
- 2 January 1985
- journal article
- research article
- Published by Wiley in Transfusion
- Vol. 25 (1) , 51-53
- https://doi.org/10.1046/j.1537-2995.1985.25185116503.x
Abstract
A 91-yr-old man developed a severe bleeding diathesis postoperatively. Laboratory studies showed an inhibitor to factor V which was identified as IgG. The patient failed to respond to fresh-frozen plasma and platelet transfusions, but demonstrated both clinical and laboratory improvement after transfusion with an activated prothrombin complex concentrate (Autoplex). Patients with refractory inhibitors to factors VIII or IX were managed successfully with this concentrate; this case demonstrates that it also may be of value in managing patients with refractory inhibitors to factor V.This publication has 17 references indexed in Scilit:
- Fatal Myocardial Necrosis Associated with Prothrombin-Complex–Concentrate Therapy in Hemophilia ANew England Journal of Medicine, 1983
- Human factor IX inhibitors: immunochemical characteristics and treatment with activated concentrateClinical and Laboratory Haematology, 1983
- The Effect of Activated Prothrombin-Complex Concentrate (FEIBA) on Joint and Muscle Bleeding in Patients with Hemophilia A and Antibodies to Factor VIIINew England Journal of Medicine, 1981
- Hazards of Prothrombin-Complex Concentrates in Treatment of HemophiliaNew England Journal of Medicine, 1981
- Antibodies to Blood Coagulation FactorsClinics in Haematology, 1979
- Acquired Inhibitors of Factor VThrombosis and Haemostasis, 1978
- Hemorrhagic death associated with a high titer factor V inhibitorAmerican Journal of Hematology, 1978
- Factor V inhibitor and bullous pemphigoid.BMJ, 1977
- Massive hemorrhage associated with circulating antibodies to factor VThe Lancet Healthy Longevity, 1973
- Factor V anticoagulants: clinical, biochemical, and immunological observationsJournal of Clinical Investigation, 1970